Seeking Alpha
  • Moving On From Pfizer's 2009 Dividend Cut
    PFE Today, 12:29 AM Valuentum Comment!

    Summary

    • Historical data is just that: history. We think investors are finally moving on from Pfizer's dividend cut in 2009.
    • We were pleased that Pfizer backed away from acquiring AstraZeneca. Its bid was way too high.
    • Pfizer's 3.5% annual dividend yield, and new therapies in the pipeline make for a combination worth paying attention to.
  • Update: Diplomat Pharmacy Announces Expansion Of IMBRUVICA And Furthers The Bull Thesis
    DPLO Yesterday, 10:44 PM Dallas Salazar 2 Comments

    Summary

    • DPLO has now announced 4 positive PRs ahead of its Q4 earnings.
    • IMBRUVICA's expansion of treatable patient population with its limited distribution should add indefinitely to DPLO's topline, which I project to be at or around $2 billion at FY14.
    • DPLO continues to treat bulls to a steady flow of good news, and I continue to be long DPLO.
  • 2 Biotech Juggernauts That Belong In Every Growth Portfolio
    BIIB, CELG Yesterday, 1:36 PM Bret Jensen 15 Comments

    Summary

    • The market has had a rough start to 2015 as the overall market has dropped some three percent in January as earnings estimates continue to be revised downward.
    • One sector that has held up well in this downdraft is the large cap biotech space which makes sense given earnings growth here is still robust and not softening.
    • Below are two biotech juggernauts that just reported excellent quarterly numbers and belong in every long term growth portfolio.
  • Catalent: Wait On Shares As Growth Issues And Messy One-Time Charges Continue To Pressure The Bottom Line
    CTLT Yesterday, 12:30 PM Dallas Salazar Comment!

    Summary

    • CTLT is an attractive surface level operation with its global presence and marquee clientele.
    • However, after a deeper look one finds a company with zero revenue growth, constant one-time charges pressuring net income, and still high leverage post-IPO delevering.
    • Wait on CTLT despite its productive chart.
  • Update: Biogen Q4 Earnings
    BIIB Yesterday, 11:50 AM Jason Russ 3 Comments

    Summary

    • Q4 2014 EPS of $4.09 per share was up 74% Y/Y; Q4 revenue was $2.64 billion, up 34% Y/Y.
    • In the last two months, several key events occurred that show the strength of Biogen's pipeline.
    • The stock continues to be reasonably valued considering the company's previous growth and its expected growth.
    • The Q4 report has confirmed my earlier bullish opinion of the stock.
  • Varian: Recalibrated Expectations, Improved Fair Value Estimate, Long-Term Hold
    VAR Yesterday, 9:27 AM Investing Doc 1 Comment

    Summary

    • Varian's operating results were stronger than they looked, with foreign exchange effects largely hiding strong underlying international growth and durable utilization trends.
    • My investment thesis, which was predicated upon steady international expansion, progressive demographic trends, and a robust and growing portfolio of intangible assets, still remains intact.
    • Despite restoring my fair value estimate to former levels, I see them as fully-valued after today's price movement, and I would wait for a discount to add to my stake.
  • Amgen Offers Impressive Upside As A New Product Cycle Begins
    AMGN Yesterday, 9:17 AM Alexander J. Poulos 12 Comments

    Summary

    • Amgen is entering into a virtuous new product cycle.
    • The plethora of new products should drive sales and earnings higher.
    • I remain bullish on the shares for reasons that will be detailed below.
  • Update: ImmunoGen Earnings
    IMGN Yesterday, 12:44 AM Clinically Sound Investor Comment!

    Summary

    • Net income and revenues smashed the consensus estimates, which was good for a 23% gain.
    • ImmunoGen goes from undervalued to fairly valued for one quarter only. Analysts just didn't know how to time when milestones would initially be recognized.
    • The increased revenue was anticipated in the original Earnings Peek, but the magnitude of the improvement was not.
  • Varian Medical - Great Growth Prospects At A Fair Price
    VAR Fri, Jan. 30, 8:34 PM The Value Investor Comment!

    Summary

    • Varian Medical reports solid results and maintains its outlook, despite severe currency headwinds.
    • This just shows that the business is performing very well on an operational basis.
    • The company operates well in long-term growing markets, which, combined with a relatively contained valuation, offers appeal.
    • Promising proton therapy developments can only provide long-term icing on the cake.
  • The 2015 Calendar Of NASH Trial Catalysts: Intercept's Breakthrough Designation Hastens Decision Process
    ICPT Fri, Jan. 30, 3:34 PM Clinically Sound Investor 9 Comments

    Summary

    • BTD for Intercept's first-in-class FXR agonist obeticholic acid (OCA) caused a spike in shares.
    • BTD shows FDA's confidence in the evidence for OCA's benefit in NASH.
    • More frequent accessibility to FDA ensures approval if the FDA sanctions the pivotal Phase 3 design and the agreed-upon primary endpoint is met.
  • Stryker Offers Good Core Growth, But Not As Much Value
    SYK Fri, Jan. 30, 2:37 PM Stephen Simpson, CFA 3 Comments

    Summary

    • Stryker's fourth quarter earnings were impacted by forex, but overall organic growth was fine and growth was strong outside of major joint recon.
    • Management has made it clear that M&A is on its to-do list, but I'm not sure the widely-speculated bid for Smith & Nephew is the best use of capital.
    • Stryker seems more or less fairly valued today and offers investors leverage to one of the better large-cap med-tech growth stories.
  • Earnings Update: Corcept Therapeutics
    CORT Fri, Jan. 30, 2:13 PM Clinically Sound Investor Comment!

    Summary

    • Corcept, a small specialized company, beat revenue estimates by $70,000.
    • Demand for Korlym, its lone product, grew by 24% quarter-over-quarter.
    • Data from a critical Korlym trial in breast cancer is expected this year.
  • Update: Celgene Continues To Have A Large Gap In Its GAAP Reporting
    CELG Fri, Jan. 30, 1:28 PM Jason Russ 19 Comments

    Summary

    • Q4 2014 EPS of $1.01 per share was up 33% Y/Y; Q4 revenue was $2.09 billion, up 18.7% Y/Y.
    • The adjusted, non-GAAP EPS that Celgene uses to report earnings was 55% higher than the GAAP EPS figure for 2014.
    • The Q4 report has confirmed my earlier neutral opinion of the stock.
  • Endocyte: Small Company, Small Valuation, Full Pipeline
    Editors' Pick ECYT Fri, Jan. 30, 1:22 PM Doug Van Cuyk 19 Comments

    Summary

    • Endocyte's cancer treatment offers big potential for investors willing to wait and take a chance.
    • The company's SMDC is an innovative technology that could change the efficacy of many chemotherapy drugs that exist today.
    • The oncology market is projected to reach $110 billion by 2018, any sliver of this market for Endocyte could be monumental for this small-cap company.
    • Endocyte has a bolus of products in the pipeline, of which many of them could produce strong revenues.
    • Endocyte is currently valued at about $220 million. As of the third-quarter 2014, the company had $211.4 million in cash/equivalents. Investors can buy the future revenue for free.
  • IPO Report: Tracon Pharmaceuticals
    TCON Fri, Jan. 30, 12:58 PM IPOdesktop 1 Comment

    Summary

    • Therapeutics for cancer, age-related macular degeneration and fibrotic diseases.
    • Collaborators include National Cancer Institute. Top line data for Phase 2 trials expected end of '15 and mid '16.
    • Relatively low price-to-book of 2.4. Relatively low cash burn rate: P/E ratio of -27. Insiders may purchase $8.2mm, 17.4%.
  • Protalex Aiming At Rheumatoid Arthritis Market With A Much Cheaper Price Tag
    PRTX Fri, Jan. 30, 12:13 PM EricFinance 2 Comments

    Summary

    • The top 3 bestselling drugs in 2013 were Abbvie's Humira, Amgen's Enbrel, and Johnson & Johnson's Remicade, all for rheumatoid arthritis [RA].
    • Many companies have tried to compete with the Big Three in the RA market, but only one has made it to blockbuster status.
    • Other RA drugs have failed to directly compete with the Big Three mainly because they are second-line therapies.
    • Protalex has an RA candidate, PRTX-100, with similar efficacy results to the Big Three so far that is estimated at 100x cheaper, with a chance of breaking into first-line.
    • Phase 2 results some time in 2015 will determine which way the stock moves.
  • Regeneron Shows Biotech Investors Have Left Their Wildcatting Days
    REGN Fri, Jan. 30, 12:12 PM Dana Blankenhorn 13 Comments

    Summary

    • Biotech has been a high-risk high-reward business like oil wildcatting was a generation ago.
    • The best investments today have multiple drugs in the market and in development.
    • Regneneron is to these companies what Schlumberger was to the oil patch.
  • One Way Johnson & Johnson Can Unlock At Least 25% Upside
    JNJ Fri, Jan. 30, 11:50 AM Investing Healthcare 22 Comments

    Summary

    • Johnson & Johnson is fairly valued as a large consumer goods company, but not as a leading biotech firm.
    • JNJ's Pharmaceutical and Consumer businesses are worth well over JNJ's entire market capitalization.
    • JNJ's Medical Device business should then be divested, leaving JNJ as two separately traded companies to unlock maximum value.
  • Envision Healthcare: A Great Play On Increased Physician Demand
    EVHC Fri, Jan. 30, 11:35 AM Real Estater Comment!

    Summary

    • Hospitals will be increasingly reliant on third party expertise that Envision can provide.
    • Envision benefits from scale through geographic and service diversity.
    • EmCare is a very high growth business with significant potential for M&A growth.
  • 3 Biotech Stocks You Won't Want To Miss In 2015
    OMED, STML, VSTM Fri, Jan. 30, 11:30 AM BPD Research 1 Comment

    Summary

    • 3 "pure-play" cancer stem cell stocks have been forgotten by investors.
    • Therapies targeting CSCs address the failures of current treatments.
    • Significant clinical catalysts in 2015 could drive substantial value increases.
    • Recently bulked up bank accounts reduce financial and dilution risk.
  • Update: Abiomed Fiscal Q3 Earnings And Impella RP FDA Approval
    ABMD Fri, Jan. 30, 11:16 AM Andy Batts Comment!

    Summary

    • Abiomed announced robust third quarter fiscal 2015 earnings along with FDA approval for Impella RP.
    • The Impella RP pump is going to be a significant revenue generator for Abiomed.
    • However, at $50 I believe a significant part of Abiomed's revenue growth is priced in.
  • Roche FY 2014 Earnings Review: What Is Driving Growth?
    RHHBY Fri, Jan. 30, 11:01 AM Stock Gazer Comment!

    Summary

    • Pharmaceutical company Roche recently reported its earnings for the final quarter and the full fiscal year 2014.
    • For the fiscal year 2014, Roche has managed to increase overall sales by 5% as compared to the same period in the previous year.
    • Incremental revenues from virology drugs (Tamiflu in particular) during the first quarter of 2015 could amount to $20 million, or a 5% revenue increase.
    • The company may generate revenues of up to $32 billion from its oncology portfolio in FY 2015.
    • Overall, a defensive stock with a decent P/E ratio, a high dividend yield and a 17% potential upside indicates that Roche is a worthwhile investment prospect.
  • IBB Is +34% For 1 Year And +7.31% For 2015 - But What Are The Risks?
    IBB Fri, Jan. 30, 10:07 AM Reuben Sushman 4 Comments

    Summary

    • Biotech and Pharma have outperformed many assets classes in the past year.
    • This ETF with over $7Bln targets firms listed on Nasdaq. With its recent re-ranking, will it continue to outperform in 2015?
    • We analyze and breakdown this well performing ETF and provide our recommendation.
  • AbbVie's Viekira Pak Has Caught Everyone's Attention
    ABBV Fri, Jan. 30, 9:10 AM Valuentum 42 Comments

    Summary

    • AbbVie is one of the strongest pharma companies on the market today.
    • With the backing of blockbuster Humira and canceling its decision to buy Shire, we think dividend growth investors are in for a treat.
    • Shares are trading below the midpoint of the fair value range, and its recent entrance into HCV could be the catalyst to drive price-to-fair value convergence.
  • IPO Preview: Spark Therapeutics
    ONCE Fri, Jan. 30, 9:02 AM IPOdesktop 3 Comments

    Summary

    • Leader in the field of gene therapy, seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments.
    • 1st product candidate targets rare blinding conditions. Phase 3 results 2nd half of '15.
    • Pfizer collaboration for hemophilia B.
  • Anatomy Of A Short (Or Long) - A Live Case Study Using Herbalife - Part 2 - Earnings Metrics
    HLF Fri, Jan. 30, 8:17 AM Paul Kindzia 38 Comments

    Summary

    • Herbalife investors (long and shorts) are highly emotionally charged.
    • Checklists and analysis can serve as an important tool during the investment process.
    • Herbalife's net income is certainly slowing.
    • The Company is no longer showing common traits of a growth stock.
  • Mylan Faces Short-Term News Flow And Reputational Risk
    MYL Fri, Jan. 30, 7:15 AM Paulo Santos 2 Comments

    Summary

    • A recent event in Europe has implications for Mylan.
    • The event can create negative news flow and reputational risk.
    • The event is likely to have a small direct impact on Mylan's revenues and profits. But the impact could spread and it could also make for negative news.
  • Civitas Solutions: Management Gets An A+ For Share Price Management But Growth Is Still A Problem, Continue To Avoid
    CIVI Fri, Jan. 30, 6:15 AM Dallas Salazar Comment!

    Summary

    • CIVI share have greatly appreciated since I recommended an avoid in mid-October but growth remains an issue.
    • CIVI has one unhealthy revenue segment, weak organic growth, a history of New Starts not maturing into meaningful growth, and stagnant cash flow growth.
    • At 38X EV/EBITDA CIVI is still an AVOID.
  • IPO Preview: Avinger
    AVGR Fri, Jan. 30, 2:47 AM IPOdesktop Comment!

    Summary

    • Medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease.
    • Rev -15%. Gross profit 39%.
    • Very high cash burn rate relative to market cap: P/E -4. Price-to-book of 3.6.
    • No insider indications to purchase on the IPO.
  • AbbVie Earnings Preview: HCV Cocktail In Focus
    ABBV Fri, Jan. 30, 2:13 AM Shock Exchange 15 Comments

    Summary

    • AbbVie reports Q4 earnings Friday before the market opens.
    • The company is heavily dependent upon HUMIRA, which currently accounts for about 65% of total revenue.
    • Its HCV treatment, Viekera Pak, was approved by the FDA in December and has been competitive in the marketplace against Gilead's Harvoni.
    • If management confirms that Viekera Pak is being prescribed in large amounts, it could drive the stock dramatically higher.
  • Winners Circle 2014 Top Hedge Fund Managers: Healthcare Funds, Nine Of Top Ten Spots
    ABMD, AAVL, ASPX Thu, Jan. 29, 8:04 PM GuruFundPicks Comment!

    Summary

    • Healthcare-focused equity hedge fund managers secured nine of the top ten spots in our 4Q/2014 update of "Winners Circle Top Performing Hedge Fund Managers."
    • Almost than half of the winnings for top-ranked Deerfield came from five core biotech company holdings, out of 110 total positions.
    • ABIOMED was the most bullish holding from among the top three ranked hedge funds, with second ranked Palo Alto Investors putting ten percent of its 13-F Assets in the stock.
    • Other fund managers from our universe of hand-picked top 330+ Wall St. fund managers have also been bullish on ABIOMED, adding to their positions in each of last three quarters.
    • Stanley Druckenmiller's Duquesne Family Office was the only non-healthcare fund that made it into the Top Ten Winners Circle list for 4Q/2014.
  • Poor Pipeline Productivity Has Left Roche More Vulnerable
    RHHBY Thu, Jan. 29, 5:07 PM Stephen Simpson, CFA 3 Comments

    Summary

    • Core sales were better than expected in the quarter, but Roche's margins were weaker than expected and the recent shift in the currency markets has created a meaningful currency headwind.
    • R&D remains a contentious point, as Roche's oncology efforts look very strong but the company's efforts outside of oncology have produced numerous recent disappointments.
    • Roche shares look fairly valued and the company really needs to reassure investors that it is on the right track with its R&D/pipeline.
  • Franchise Fortunes Mark Shifts In Consensus For Marketed Products
    SNY, ABBV, MRK Thu, Jan. 29, 4:48 PM EP Vantage Comment!
  • Earnings Peek: Stay With Ligand Pharmaceuticals For A Year Or Three
    LGND Thu, Jan. 29, 4:27 PM Clinically Sound Investor 1 Comment

    Summary

    • Ligand has many significant royalty-generating collaborations. Revenues are seen to increase ~30% annually.
    • Partners like Pfizer, Merck, GlaxoSmithKline, and Amgen do all the trials and selling, which keeps Ligand's gross margins near 90%.
    • Royalty rates escalate with higher sales, which is why growth likely won't just be linear. Several of Ligand's partnered assets may close in on blockbuster status in a few years.
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon
    CTIX Thu, Jan. 29, 4:13 PM KarinCA 81 Comments

    Summary

    • Shorters used eye-catching headlines with irrelevant information.
    • Cellceutix in clinical trials with a multi-billion-dollar pipeline potential.
    • Many catalysts could trigger a short squeeze, which will catapult the company to new highs.
  • The Medicines Company: Raplixa Approval Is Likely, Manufacturing Risk Is Low
    MDCO Thu, Jan. 29, 4:13 PM Beacon VP Investments Comment!

    Summary

    • Raplixa has advantages on transportation, storage and application over current available fibrin sealants.
    • Raplixa shows promising efficacy and safety results in both Phase 2 and Phase 3 clinical studies.
    • Although FDA has strict regulations on blood donors and plasma-derived products, the manufacturing partners for Raplixa are likely to meet the requirements.
    • An article recently published by another contributor states a similar positive opinion on the product.
  • Update: Baxter Q4 2014 Earnings Impress, But Guidance Disappoints
    BAX Thu, Jan. 29, 3:44 PM Trevor Lowenthal 10 Comments

    Summary

    • Baxter reported today Q4 2014 earnings, exceeding both earnings and revenue estimates.
    • The company warned that revenues will take a three percent hit this quarter primarily due to foreign exchange rates and generic competition. Needless to say, this forecast is worrisome.
    • I did not anticipate this negative forecast in my initial report.
    • As shares trade higher, it may be wise to take profits in the coming weeks and reposition following the Q1 2015 earnings report.
  • Sientra: A Breast Implant Pure-Play With A Technologically Superior Implant, Initiating Bullish
    SIEN Thu, Jan. 29, 3:43 PM Dallas Salazar 2 Comments

    Summary

    • SIEN is just one of now three FDA approved competitors selling breast implants in the US.
    • SIEN has a better implant that retains its shape, fractures at a greater force resistance, and that can be softer than its competitors products.
    • SIEN's implants are also safer - demonstrating lower rupture rates in total, a lower rate of capsular contraction, and a lower rate of reported incidents needing reoperations.
    • SIEN is a new, differentiated player in a well-developed, high barrier to entry space - BUY SIEN and hold on for the ride higher.
  • Earnings Peek: Don't Expect Incyte To Be Profitable In 2014
    INCY Thu, Jan. 29, 2:20 PM Clinically Sound Investor 4 Comments

    Summary

    • Revenue from Jakafi is continually increasing, but guidance is muted for the fourth quarter of 2014.
    • Many readouts from pivotal and proof of concept trials will occur in 2015 or 2016.
    • Incyte is sharing costs to develop two very promising advanced candidates.
  • Abbott Laboratories Q4 Results: Double-Digit Growth Despite Headwinds
    ABT Thu, Jan. 29, 1:35 PM Sure Dividend 1 Comment

    Summary

    • Adjusted EPS increased 22.4% versus the same quarter a year ago for Abbott Laboratories.
    • The company recently increased its dividend payments from $0.88 a share per year to $0.96 a share per year.
    • Will a strong U.S. Dollar halt Abbott Laboratories growth?
  • A Snapshot Of Infraredx's IPO: Consider Holding Off
    REDX Thu, Jan. 29, 12:39 PM Don Dion Comment!

    Summary

    • MA-based cardiovascular imaging company REDX is set to IPO Thurs., 1.29; lead underwriters include BMO Capital Markets, RBC and Cannacord.
    • REDX focuses on identifying LCPs, which many cardiologists claim to be a major cause of heart attacks.
    • Major competitors include Boston Scientific, St. Jude Medical, Volcano Corp., ACIST Medical, and Terumo.
    • We suggest investors consider holding off on this IPO.
  • Natus Medical Has The Right Growth Metrics BABY
    BABY Thu, Jan. 29, 12:10 PM Chris Katje Comment!

    Summary

    • Natus Medical extended its business segments with two recent acquisitions.
    • Company's large scale and hospital relationships give a chance to make acquisitions large revenue opportunities.
    • Continued margin expansion and retirement of debt shows strong financial position.
  • Race For A Cure: Tracon Pharmaceuticals IPO
    TCON Thu, Jan. 29, 11:59 AM Don Dion Comment!

    Summary

    • San-Diego-based TCON is set to price its IPO Thurs., 1.29; underwriters include Wells Fargo, Stifel Oppenheimer, and Needham.
    • TCON is a clinical stage biotech company focused on endoglin biology (seeking to control the process of new blood vessel formation -- key to fibrosis, lung cancer, and other diseases).
    • TCON has posted collaboration revenues but will not see clear profits until it commercializes additional products; the pipeline is strong.
    • Following a record year for biotech IPOs, we suggest investors consider buying into this one.
  • Unilife: Ready For Phase 2 Of A Huge Move
    UNIS Thu, Jan. 29, 11:44 AM RightEdge Analytics 8 Comments

    Summary

    • The recent strategic agreement with AbbVie could provide the building blocks for another blockbuster deal, similar to the Sanofi contract.
    • New CFO David Hastings increased share price at Incyte 20x over his tenure and we expect similar results at Unilife.
    • The blockbuster Sanofi agreement for wearable injectors is beginning in clinical trials and will possibly contribute some revenues this quarter.
    • In the prior conference call the CEO stated that the Sanofi and Hikma contracts for a total of 325 million units of Unifill per year will show revenue this quarter.
    • Big investors are starting to take notice with JP Morgan becoming a 10% owner this quarter and Frontier Capital adding 4 million shares.
  • ContraFect: An Emerging Anti-Infectious Biotechnology Company With 2 Unique Platforms Targeting Multi-Drug Resistance
    Editors' Pick CFRX Thu, Jan. 29, 11:06 AM Tony Schwartz, PhD 2 Comments

    Summary

    • ContraFect has developed a unique and novel pipeline for the treatment of bacterial infections, biofilms and influenza.
    • The FDA gave the go-ahead to initiate a Phase I trial with its lead candidate, CF-301, to begin in the first quarter of 2015.
    • Initiation of its Phase I human trial using CF-401 for influenza should begin in 2016. Pre-clinical studies demonstrated superior efficacy over its competitor's drug.
  • Dear Pamela Jones Harbour: Why Don't Canadians Drink Formula 1?
    HLF Thu, Jan. 29, 11:03 AM Matt Stewart 173 Comments

    Summary

    • How would a legitimate global weight loss company function?
    • What sorts of markets would be successful?
    • What might the man in the moon say?
  • Progress From Accuray, But Still No Big Turn
    ARAY Thu, Jan. 29, 9:50 AM Stephen Simpson, CFA Comment!

    Summary

    • Revenue growth is still lackluster, but orders appear to be stabilizing and margins should continue to improve.
    • A commercial launch of the multileaf collimator remains a major near-term event for the company, but riding the longer-term adoption curve of SRS/SBRT is the critical driver.
    • Competing against an entrenched rival like Varian is extremely challenging, but long-term mid-teens market share can support a double-digit fair value today.
  • Why Is MusclePharm Doing So Badly? Here's My Best Guess
    MSLP Thu, Jan. 29, 9:12 AM Paulo Santos 63 Comments

    Summary

    • MusclePharm stock has been doing much worse than expected.
    • This, along with other circumstantial evidence, has led to fears and doubts on my part.
    • In this article I explain what could have gone wrong, and what could confirm or dispel these fears.
  • Presbia Puts Your Reading Glasses In Your Eyeball
    LENS Thu, Jan. 29, 9:02 AM IPO Candy 1 Comment

    Summary

    • Presbia has an attractive minimally invasive laser surgery to tuck a micro-lens right into your eye.
    • This is a large (~$28B) market opportunity that addresses a widespread problem of middle-age.
    • Presbia is in the midst of late stage (Phase 3) clinical trials to commercialize the product.
    • Prospective margins are good with a $700-800 all in cost and $2000-3000 procedure price.
    • There are always risks in terms of trial success, customer adoption and pricing so please consider these and the full prospectus before investing.
  • Jazz Pharmaceuticals: Upside Opportunities
    JAZZ Thu, Jan. 29, 8:55 AM Max Grigoryev 6 Comments

    Summary

    • Strong financial performance during 2014 with 34% revenue growth and 57% EBITDA margin.
    • Market leadership and absence of competition in markets of particular drugs treating cataplexy, EDS and ALL with hypersensitivity.
    • Solid manufacturing base and doubled R&D costs during 2014.